

May 07, 2026

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400051
(SYMBOL: THYROCARE)

BSE Limited
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400001
(SCRIP CODE: 539871)

Subject: Outcome of the Board Meeting held on Thursday, May 07, 2026

1. Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended on March 31, 2026;
2. Recommendation for the payment of final dividend;
3. Appointment of M/s. Price Waterhouse Chartered Accountants LLP, as the Statutory Auditors of the Company for first term of five consecutive years;
4. Appointment of Cost Auditors for the financial year 2026-27;
5. Re-appointment of Mr. Rahul Franklin Guha (DIN:09588432), as Chairman, Managing Director & Chief Executive Officer of the Company;
6. Appointment of Mr. Uday Patel Kadam (DIN: 09277168) as an Additional Director in the category of Non-Executive, Non-Independent Director of the Company;
7. Appointment of Mr. Gaurav Verma (DIN: 11692586) as an Additional Director in the category of Non-Executive, Non-Independent Director of the Company;
8. Resignation of Mr. Dharmil Nirupam Sheth (DIN: 06999772), Non-Executive, Non-Independent Director of the Company;
9. Resignation of Dr. Dhaval Rajesh Shah (DIN: 07485688), Non-Executive, Non-Independent Director of the Company;
10. Investment in the equity shares of Think Health Diagnostics Private Limited, a Wholly Owned Subsidiary of the Company;
11. Alteration of the Memorandum of Association of the Company.

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**Listing Regulations**"), we wish to inform you that the Board of Directors of the Company ("**Board**"), at its meeting held today, i.e., Thursday, May 07, 2026, inter alia, considered and approved the following matters:

1. Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended on March 31, 2026

The Board, based on the recommendation of the Audit Committee, has considered and approved the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2026.

Pursuant to Regulation 33(3) of the Listing Regulations, copies of the Audited Standalone and Consolidated financial results for the quarter and financial year ended March 31, 2026, along with the Auditors' Report on the said financial results issued by the Statutory Auditors of the Company are attached as **Annexure - 1**.

The Statutory Auditors of the Company, M/s. M S K A & Associates LLP, Chartered Accountants have issued an unmodified opinion on the Audited Financial Results (standalone & consolidated) for the quarter and financial year ended March 31, 2026.

A declaration from the Chief Financial Officer confirming that the Audit Reports on the said financial results contain an unmodified opinion is enclosed as **Annexure – 2**.

The aforesaid Audited Financial Results and Auditors' Report are also being made available on the website of the Company at <https://investor.thyrocare.com/financials/quarterly-financial-results/>.

2. Recommendation for the payment of final dividend

The Board has recommended a final dividend of **Rs. 7.00 per equity share** for the financial year 2025–26, subject to the approval of the shareholders at the ensuing Annual General Meeting (“AGM”) of the Company. The dividend, if declared, shall be paid within 30 days from the date of the AGM. The record date for determining the eligibility of members entitled to receive the dividend on equity shares will be intimated separately.

The Company has already paid an interim dividend of Rs. 7.00 per equity share (pre-bonus issue; equivalent to Rs. 2.33 per share post bonus adjustment) on equity shares of face value Rs. 10 each for the financial year 2025-26. Accordingly, the total dividend for the financial year ended March 31, 2026, would aggregate to Rs. 9.33 per equity share (post bonus adjustment) on equity shares of face value Rs. 10 each, subject to approval of the final dividend by the shareholders.

3. Appointment of M/s. Price Waterhouse Chartered Accountants LLP, as the Statutory Auditors of the Company for first term of five consecutive years;

Based on the recommendation of the Audit Committee, the Board has considered and approved, and further recommended to the shareholders for their approval at the ensuing Annual General Meeting (“AGM”), the appointment of **M/s. Price Waterhouse Chartered Accountants LLP** (ICAI Firm Registration No. 012754N/N500016) as the Statutory Auditors of the Company for first term of five consecutive years, commencing from the conclusion of the 26th AGM (to be held in the calendar year 2026) until the conclusion of the 31st AGM (to be held in the calendar year 2031), subject to the approval of the shareholders and other applicable statutory requirements.

It is further informed that **M/s. M S K A & Associates LLP**, Chartered Accountants (ICAI Firm Registration No. 105047W/W101187), the existing Statutory Auditors of the Company, who were appointed for a first term of five (5) consecutive years at the 21st AGM held on June 26, 2021, shall complete their term at the conclusion of the 26th AGM of the Company to be held in the calendar year 2026.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, is annexed as **Annexure- 3**.

4. Appointment of Cost Auditors for the financial year 2026-27

Based on the recommendation of the Audit Committee, the Board has approved the appointment of **M/s. Jitender Navneet & Co.**, Cost Accountants (FRN: 000119), as the Cost Auditor of the Company for the Financial Year 2026-27.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, is annexed as **Annexure- 4**.

5. Re-appointment of Mr. Rahul Franklin Guha, (DIN: 09588432) as Chairman, Managing Director & CEO of the Company

Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the re-appointment of Mr. Rahul Franklin Guha (DIN: 09588432) as Chairman, Managing Director & Chief Executive Officer of the Company, for a further period of five (5) years commencing from May 4, 2027 to May 3, 2032 (both days inclusive), subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. He shall not be liable to retire by rotation.

Further, in terms of the respective circular(s) dated June 20, 2018, issued by BSE Limited, Ref. No. LIST/COMP/14/2018-19 and by National Stock Exchange of India Limited, Ref. No. NSE/CML/2018/24, it is hereby confirmed that Mr. Rahul Franklin Guha is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India ("SEBI") or any other statutory authority/ court.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, is annexed as **Annexure- 5**.

6. Appointment of Mr. Uday Patel Kadam (DIN: 09277168) as an Additional Director in the category of Non-Executive, Non-Independent Director of the Company

Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Uday Patel Kadam (DIN: 09277168) as an Additional Director in the category of Non-Executive, Non-Independent Director on the Board of the Company with effect from May 8, 2026. He shall be liable to retire by rotation, and his appointment is subject to the approval of the shareholders of the Company within three months from the effective date of appointment.

Further, in terms of the respective circulars dated June 20, 2018, issued by BSE Limited (Ref. No. LIST/COMP/14/2018-19) and National Stock Exchange of India Limited (Ref. No. NSE/CML/2018/24), it is hereby confirmed that Mr. Uday Patel Kadam is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India ("SEBI") or any other statutory authority/court.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, is annexed as **Annexure- 6**.

7. Appointment of Mr. Gaurav Verma (DIN: 11692586) as an Additional Director in the category of Non-Executive, Non-Independent Director of the Company

Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Gaurav Verma (DIN: 11692586) as an Additional Director in the category of Non-Executive, Non-Independent Director on the Board of the Company with effect from May 8, 2026. He shall be liable to retire by rotation, and his appointment is subject to the approval of the shareholders of the Company within three months from the effective date of appointment.

Further, in terms of the respective circulars dated June 20, 2018, issued by BSE Limited (Ref. No. LIST/COMP/14/2018-19) and National Stock Exchange of India Limited (Ref. No. NSE/CML/2018/24), it is hereby confirmed that Mr. Gaurav Verma is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India ("SEBI") or any other statutory authority/court.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, is annexed as **Annexure- 7.**

8. Resignation of Mr. Dharmil Nirupam Sheth (DIN: 06999772), Non-Executive, Non-Independent Director of the Company

The Board took note of the resignation of Mr. Dharmil Nirupam Sheth (DIN: 06999772), Non-Executive, Non-Independent Director of the Company, who has tendered his resignation due to pre-occupation and other commitments, with effect from the close of business hours on May 07, 2026.

A copy of the resignation letter received from Mr. Dharmil Nirupam Sheth is enclosed as **Annexure 8.**

The Company has also received confirmation from Mr. Dharmil Nirupam Sheth that there are no material reasons for his resignation other than those stated in his resignation letter dated April 30, 2026.

Consequent to his resignation, he shall also cease to be a member of the following Committees of the Board:

- Nomination and Remuneration Committee
- Stakeholders' Relationship Committee
- Risk Management Committee

The Board placed on record its sincere appreciation for the valuable contributions made by Mr. Dharmil Nirupam Sheth during his tenure.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, is annexed as **Annexure- 9.**

9. Resignation of Dr. Dhaval Rajesh Shah (DIN: 07485688), Non-Executive, Non-Independent Director of the Company

The Board took note of the resignation of Dr. Dhaval Rajesh Shah (DIN: 07485688), Non-Executive, Non-Independent Director of the Company, who has tendered his resignation due to pre-occupation and other commitments, with effect from the close of business hours on May 07, 2026.

A copy of the resignation letter received from Dr. Dhaval Rajesh Shah is enclosed as **Annexure 10**.

The Company has also received confirmation from Dr. Dhaval Rajesh Shah that there are no material reasons for his resignation other than those stated in his resignation letter dated April 30, 2026.

Consequent to his resignation, he shall also cease to be a member of the Corporate Social Responsibility Committee of the Board.

The Board placed on record its sincere appreciation for the valuable contributions made by Dr. Dhaval Rajesh Shah during his tenure.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is annexed as **Annexure- 11**.

10. Investment in the equity shares of Think Health Diagnostics Private Limited, a Wholly Owned Subsidiary of the Company

The Board has approved an investment by way of subscription to the equity shares of Think Health Diagnostics Private Limited ("Think Health"), a wholly owned subsidiary of the Company, for an amount not exceeding Rs. 5,50,00,000 (Rupees Five Crores Fifty Lakhs only), in one or more tranches, in compliance with applicable laws.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is annexed as **Annexure- 12**.

11. Alteration of the Memorandum of Association of the Company

The Board has approved the alteration of the Memorandum of Association ("MOA") of the Company, subject to the approval of the shareholders and such other statutory/regulatory approvals, as may be required.

The existing MOA is based on the provisions of the erstwhile Companies Act, 1956 and requires alignment with the provisions of the Companies Act, 2013. Accordingly, the proposed amendments include updating references and relevant clauses in line with the Companies Act, 2013.

Further, while the existing Objects Clause already covers diagnostic activities, it is proposed to broaden its scope by inserting an enabling sub-clause under Clause III(A) to permit the Company to undertake a wider range of activities within the healthcare and diagnostics ecosystem, including allied services and dealing in related products, equipment, and consumables.

Accordingly, the following key changes are proposed in the MOA:

Particulars	Existing Clauses	Proposed Amendments
Substitution of heading of Clause III(A)	MAIN OBJECTS OF THE COMPANY TO BE PURSUED BY THE COMPANY ON ITS INCORPORATION	THE OBJECTS TO BE PURSUED BY THE COMPANY ARE
Addition of Sub clause 1B under Clause III(A)(1)		1B To carry on the business of establishing, setting up, acquiring, operating, managing or administering diagnostic facilities (including home collection), including but not limited to, clinical laboratories, radiology and pathology centres, collection centres, hospitals, clinics, polyclinics, research and healthcare facilities, and to provide healthcare and diagnostic services including pathological, radiological, biochemical, microbiological, immunological, genetic, cardiological and other medical investigations and testing services, and to undertake collection, handling, storage, transportation, processing and analysis of human, animal, plant, food, water, soil and other samples, tissues, body fluids, blood and allied materials for diagnostic, therapeutic, research or other purposes, in India or abroad, under its own brand or otherwise, including through online or digital platforms; and to develop, operate and manage healthcare, diagnostic and data-driven digital platforms, applications and portals; and to undertake teaching, training and imparting practical and theoretical knowledge in diagnostics, pathology, healthcare and allied fields; and further to manufacture, produce, assemble, process, procure, purchase, import, export, stock, distribute, market, sell, resell, lease, hire or otherwise deal in medical, diagnostic, healthcare, pharmaceutical, surgical, wellness equipment, devices, instruments, consumables, merchandise and allied products, including point of care devices, and to carry on such activities either on its own or in collaboration with third parties, partners, franchisees or service providers in India or abroad.
Substitution of heading of Clause III(B)	Object incidental or ancillary to the attainment of main objects:	Matters which are necessary for furtherance of the objects specified in Clause III(A) are:
Deletion of header of Clause III(C) i.e., "Other Objects"	Other Objects:	Deleted in line with the Companies Act, 2013, as such clauses are now covered under Clause III(B)
Substitution of Clause IV	The liability of the members is limited	The Liability of members is limited and this liability is limited to the amount unpaid, if any, on the shares held by them.
Statutory alignment	References to Companies Act, 1956	To be replaced with corresponding provisions of the Companies Act, 2013 along with necessary consequential changes



Tests you can trust

The above disclosures are also being made available on the website of the Company at <https://investor.thyrocare.com>.

The Board Meeting commenced at 03: 35 P.M. and concluded at 05:40 P.M.

This is for your information and records.

Yours Faithfully,
For **Thyrocare Technologies Limited**,



Brijesh Kumar
Company Secretary and Compliance Officer
Encl. A/a

Thyrocare Technologies Limited

📍 D-37/1, TTC MIDC, Turbhe, Navi Mumbai- 400 703, India 📞 022- 3090 0000

✉️ enquiry@thyrocare.com 🌐 www.thyrocare.com

(CIN : L85110MH2000PLC123882)

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Thyrocare Technologies Limited

Report on the Audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying Standalone Annual Financial Results of Thyrocare Technologies Limited (hereinafter referred to as 'the Company') for the year ended March 31, 2026, ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us the aforesaid Statement:

(i) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(ii) gives a true and fair view, in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the net profit, and other comprehensive income and other financial information of the Company for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Standalone Financial Results

This Statement has been prepared on the basis of the Standalone Annual Financial Statements. The Company's Management and Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit, and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian



MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and is in compliance with the Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and

application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to Standalone Financial Statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



MSK A & Associates LLP

(Formerly known as M S K A & Associates)
Chartered Accountants

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter(s):

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187


Ojas D. Joshi

Partner

Membership No.: 109752

UDIN: 26109752KPBHA13153

Place: Navi Mumbai

Date: May 07, 2026



THYROCARE TECHNOLOGIES LIMITED

Registered Office: D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Corporate Office: D/37-3, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Tel: (91 22) 2762 2762 | Fax: (91 22) 2768 2409

Website: www.thyrocare.com

E-mail: kumar.brijesh@thyrocare.com

Corporate Identity Number: L85110MH2000PLC123882

Statement of Audited Standalone Financial Results for the Quarter and Year Ended 31 March 2026

(Rs. in Crores)

Particulars	Quarter ended			Year ended	Year ended
	31 March 2026 (Audited)	31 December 2025 (Reviewed)	31 March 2025(Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)
Revenue from operations	210.67	182.48	173.87	774.27	633.10
Other Income	3.72	3.43	4.54	13.39	13.34
1 Total income	214.39	185.91	178.41	787.66	646.44
Expenses					
(a) Cost of materials consumed	54.27	44.61	46.19	208.37	177.28
(b) Purchase of stock-in-trade	0.77	0.04	0.46	1.09	2.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(0.51)	0.09	0.30	(0.23)	0.81
(d) Employee benefits expense	33.44	32.78	31.33	128.29	118.56
(e) Finance cost	1.43	(0.47)	0.60	2.18	2.63
(f) Depreciation and amortisation expense	12.94	19.58	11.78	51.17	46.52
(g) Other expenses	50.07	46.69	39.95	180.42	147.43
2 Total Expenses	152.41	143.32	130.61	571.29	495.23
3 Profit before exceptional items and tax (1 - 2)	61.98	42.59	47.80	216.37	151.21
Exceptional Items	-	5.97	-	5.97	-
4 Profit after exceptional items and before tax	61.98	36.62	47.80	210.40	151.21
5 Tax expense					
(a) Current tax expense (including adjustment of earlier years)	(16.05)	(9.95)	(14.43)	(57.29)	(47.77)
(b) Deferred tax credit/(charge) (refer to note 4 below)	(2.35)	(0.52)	(11.42)	(4.30)	(7.66)
6 Profit for the period/year (4 - 5)	43.58	26.15	21.95	148.81	95.78
7 Other comprehensive income (net of tax)					
(a) Items that will not be reclassified to profit or loss	0.64	(0.16)	(0.31)	0.29	(0.97)
(b) Income tax relating to items that will not be reclassified to profit or loss	(0.16)	0.04	0.08	(0.07)	0.24
8 Total comprehensive income for the period/ year comprising of profit and other comprehensive income for the period/ year (6 + 7)	44.06	26.03	21.72	149.03	95.05
Paid-up equity share capital (Face Value of Rs. 10/- each)	159.17	159.16	52.99	159.17	52.99
Other equity	-	-	-	401.51	484.11
9 Earnings Per Share (of Rs. 10/- each):#					
(a) Basic (in Rs.)	2.75	1.64	1.36	9.36	5.98
(b) Diluted (in Rs.)	2.75	1.63	1.35	9.34	5.96
See accompanying note to the Financial Results					

#not audited except for the year ended 31 March 2026 and 31 March 2025.

Notes :

- The above audited standalone financial results of the Company were audited and recommended by the Audit Committee on 7 May 2026 and subsequently approved by the Board of Directors at its meeting held on 7 May 2026. The statutory auditors of the Company have expressed an unmodified opinion on the audited standalone financial results for the quarter and year ended 31 March 2026.
- The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between audited figures in respect of the full financial year and the limited reviewed year to date figures up to the quarter ended 31 December 2025 and 31 December 2024 respectively.
- These audited standalone financial results have been prepared in compliance with the recognition and remeasurement principles of Ind AS as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India, to the extent applicable.
- The Company has assessed the recoverable amount of the investment made in its wholly owned subsidiary Nuclear Healthcare Limited ("NHL") as value in use, being the higher of Fair Value less Cost of Disposal and Value in Use. For the year ended 31 March 2026, NHL has reported earning before interest tax and depreciation of Rs 6.15 Crores and has generated cash inflow from operating activities amounting to Rs. 10.67 Crores. NHL still has accumulated losses carried forward from the previous years, hence the Company continues to assess the profitability and growth of NHL. The management does not foresee any further requirement of impairment of its investment made in NHL as at 31 March 2026 other than those already provided for in the books of account amounting to Rs. 44.33 Crores (31 March 2025: INR 44.33 Crores). The deferred tax asset created against the impairment of investment made in NHL in the earlier financial years amounting to Rs. 11.16 Crores has been reversed in the previous financial year. The impact of the same is forming part of previous year deferred tax charge.



5 Effective 21 November 2025, The Government of India has consolidated multiple existing labour laws into an unified framework comprising four Labour Codes viz the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 collectively referred to as the 'New Labour Codes'. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations.

The Company has assessed the incremental impact of these changes on the basis of the information available and actuarial valuation report obtained from an independent valuer, consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality, its origination due to regulatory changes and non-recurring nature of this impact, the Company has presented such incremental impact as "Exceptional Items" in the audited standalone financial results for the year ended 31 March 2026. Accordingly the Exceptional Items includes of Rs. 4.01 Crores as incremental impact of Gratuity arising primarily due to the change in the definition of wages.

Further Exceptional Items also include Rs. 1.96 Crores which are non recurring costs associated with restructuring of capital during the year ended 31 March 2026.

- 6 During the quarter and year ended 31 March 2026, the Company has forfeited 5,196 equity stock options and 25,172 equity stock options respectively granted to employees under Employee Stock Option schemes but not vested on account of discontinuance of services of these employees, which has been added back to the pool and the same would be available for subsequent distribution subject to statutory rules and regulations, as applicable.
- 7 During the year ended 31 March 2026, the Company has allotted 63,074 equity shares of Rs.10/- each pursuant to the exercise of options by the grantees under the Employee Stock Option Scheme.
- 8 In accordance with Ind AS 108 'Operating Segments', segment information has been given in the unaudited consolidated financial results of the Group.
- 9 The earning per share in respect of previous quarters / years has been restated considering the allotment of bonus shares and adjustment in respect of outstanding stock options, in line with the requirements of Ind AS 33 "Earnings Per Share".
- 10 The Board of directors have recommended a final dividend of Rs. 7 per equity share of face value of Rs. 10 each for the year ended 31 March 2026 subject to the approval of shareholders at the ensuing shareholders meeting.
- 11 The audited standalone financial results are available on the website of the Company (www.thyrocare.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com).

By order of the Board
For Thyrocare Technologies Limited
CIN - L85110MH2000PLC123882



Rahul Guha
Managing Director
DIN - 09588432
Navi Mumbai, 7 May 2026



Audited Standalone Statement of Assets and Liabilities as at 31 March 2026

(Rs. in Crores)

Particulars		As at	As at
		31 March 2026 (Audited)	31 March 2025 (Audited)
A	ASSETS		
i	Non-current assets		
(a)	Property, plant and equipment	113.56	113.66
(b)	Capital work-in progress	3.07	14.17
(c)	Investment property	0.92	0.96
(d)	Goodwill	4.18	4.18
(e)	Other intangible assets	3.35	4.54
(f)	Right-of-use assets	58.40	34.21
(g)	Investment in associate and jointly controlled entity	20.00	23.12
(h)	Financial assets		
	Investments	167.04	156.71
	Other financial assets	5.60	6.63
(i)	Deferred tax assets (net)	12.71	17.08
(j)	Other tax assets	4.15	1.10
(k)	Other non-current assets	2.42	1.43
		395.40	377.79
ii	Current assets		
(a)	Inventories	46.56	45.70
(b)	Financial assets		
	Investments	106.83	103.97
	Trade receivables	69.53	68.94
	Cash and cash equivalents	32.88	15.18
	Bank balances other than cash and cash equivalents	29.75	36.80
	Other financial assets	1.21	1.04
(c)	Other current assets	29.05	26.93
		315.81	298.56
	TOTAL ASSETS	711.21	676.35
B	EQUITY		
i	Equity share capital	159.17	52.99
ii	Other equity	401.51	484.11
	Total Equity	560.68	537.10
C	LIABILITIES		
i	Non-current liabilities		
(a)	Financial liabilities		
	Lease liabilities	38.32	16.70
(b)	Provisions	11.79	5.00
(c)	Other financial liabilities	5.00	6.59
		55.11	28.29
	Current liabilities		
(a)	Financial liabilities		
	Short-term borrowings	-	-
	Lease liabilities	9.86	6.51
	Trade payables		
	Total outstanding dues to micro and small enterprises	5.76	2.56
	Total outstanding dues to creditors other than micro and small enterprises	49.37	67.04
	Other financial liabilities	12.77	14.32
(b)	Contract Liabilities	10.60	13.56
(c)	Current tax liabilities (net)	2.38	2.38
(d)	Provisions	1.25	0.98
(e)	Other current liabilities	3.43	3.61
		95.42	110.96
	TOTAL EQUITY AND LIABILITIES	711.21	676.35

By order of the Board
For Thyrocare Technologies Limited
CIN - L85110MH2000PLC123882



Rahul Guha
Managing Director
DIN - 09588432
Navi Mumbai, 7 May 2026



Audited Standalone Statement of Cash Flows for the Year ended 31 March 2026

(Rs. in Crores)

Particulars		As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
A.	Cash flows from operating activities		
	Net profit before exceptional items and income tax	210.40	151.21
	Adjustments for:		
	Depreciation and amortisation	51.17	46.52
	Net (gain) on investments	(0.30)	(0.72)
	(Profit)/Loss on sale of property, plant and equipment	(3.10)	(0.01)
	Impairment loss allowance on financial assets	(2.15)	1.07
	Employee stock compensation expense	22.56	23.48
	Finance costs	2.15	2.65
	Interest income	(3.06)	(1.38)
	Profit on sale of short term investment	(5.14)	-
	Total of Profit & Loss adjustment	62.13	71.61
	Operating profit before working capital changes	272.53	222.82
	Adjustments for:		
	(Increase) in Inventories	(0.86)	(0.00)*
	Decrease / (Increase) in Trade receivables	1.57	(29.81)
	Decrease/(Increase) in Other assets	4.77	(5.44)
	(Decrease)/Increase in Trade payables	(14.75)	33.65
	(Decrease)/Increase in Other liabilities	(2.67)	5.44
	Increase in Provisions	5.77	0.98
	Net Working Capital Movement	(6.17)	4.82
	Cash generated from operations	266.36	227.64
	Tax paid (net of refunds)	(60.29)	(49.00)
	Net cash flows generated from operating activities (A)	206.07	178.64
B.	Purchase of property, plant and equipment, additions to capital work-in-progress and capital advances	(18.93)	(34.83)
	Proceeds from sale of property, plant and equipment	4.06	0.01
	Sale/(Purchase) of current investments (net)	2.87	12.01
	Consideration paid on acquisition of Polo & Vinda Business	-	(11.26)
	Investment in associate and jointly controlled entity	(7.22)	(3.63)
	(Investment in)/proceeds from maturity of term deposits	(4.76)	(6.27)
	Interest received	3.06	1.39
	Net cash (used in) investing activities (B)	(20.92)	(42.58)
	Cash flows from financing activities		
	Proceeds from issue of equity shares	-	0.04
	Repayment of borrowings	-	(19.76)
	Payment towards principal portion of lease liabilities	(16.87)	(6.76)
	Payment towards interest portion of lease liabilities	(2.15)	(2.22)
	Interest Paid	-	(0.43)
	Dividend paid to the shareholders	(148.43)	(95.31)
	Net cash (used in) financing activities (C)	(167.45)	(124.44)
	Net Increase in Cash and cash equivalents (A+B+C)	17.70	11.62
	Cash and cash equivalents at the beginning of the year	15.18	3.56
	Cash and cash equivalents at the end of the year	32.88	15.18

* Represents amounts less than Rs. 0.01 crores.



By order of the Board
For Thyrocare Technologies Limited
CIN - L85110MH2000PLC123882

Rahul Guha

Rahul Guha
Managing Director
DIN - 09588432
Navi Mumbai, 7 May 2026

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Thyrocare Technologies Limited

Report on the Audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying Consolidated Annual Financial Results of Thyrocare Technologies Limited (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), its associate for the year ended March 31, 2026, ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditors on separate audited Financial Statements of the subsidiaries and associate, the aforesaid Statement:

(a) includes the annual financial results of the Holding Company and the following entities:

Sr. No.	Name of the Entity	Relationship with the Holding Company
1.	Nueclear Healthcare Limited	Wholly Owned Subsidiary
2.	Think Health Diagnostic Private Limited	Wholly Owned Subsidiary
3.	Pulse Hitech Health Services (Ghatkopar) LLP	Subsidiary
4.	Thyrocare Laboratories (Tanzania) Limited	Subsidiary
5.	Equinox Labs Private Limited	Associate

(ii) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the consolidated net profit, and consolidated other comprehensive income and other financial information of the Group, its associate for the year ended March 31, 2026.



MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the consolidated financial results section of our report. We are independent of the Group, its associate in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Consolidated Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management and Board of Directors' Responsibilities for the Consolidated Financial Results

This Statement has been prepared on the basis of the Consolidated Annual Financial Statements. The Holding Company's Management and Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the consolidated net profit, and consolidated other comprehensive income and other financial information of the Group, its associate in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and is in compliance with the Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Management and Board of Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of the Group and its associate to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associate are responsible for overseeing the financial reporting process of each company.



MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group and its associate to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.



MSKA & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matters:

The Statement includes the audited Financial Statements of two subsidiaries whose Financial Statements reflect total assets of Rs. 7.77 Crores as at March 31, 2026, total revenue of Rs. 8.53 Crores, net loss after tax of Rs. 0.18 Crores, total comprehensive loss of Rs. 0.18 Crores and net cash inflow of Rs. 0.17 Crores for the year ended on that date respectively, as considered in the Statement, which have been audited by the other auditors. The other auditors' reports on the Financial Statements of these entities have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of such other auditors and the procedures performed by us are as stated in paragraph above.

The Statement includes the audited Financial Statements of one associate whose Financial Statements reflect Group's share of net profit after tax of Rs. 1.39 Crores, and Group's share of total comprehensive income of Rs. 1.39 Crores for the year ended March 31, 2026, as considered in the Statement, which have been audited by the other auditor. The other auditor's reports on the Financial Statements of these entities have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associate is based solely on the report of such other auditor and the procedures performed by us are as stated in paragraph above.

The Statement includes the unaudited Financial Information of one foreign subsidiary whose Financial Information reflect total assets of Rs. 6.40 Crores as at March 31, 2026, total revenue of Rs. 2.73 Crores, net loss after tax of Rs. 4.53 Crores, total comprehensive loss of Rs. 4.53 Crores, and net cash inflow of Rs. 2.50 Crores for the year ended on that date respectively, as considered in the Statement. These unaudited Financial Information have been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on such unaudited Financial Information. In our opinion and according to the information and explanations given to us by the Management, these Financial Information are not material to the Group.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Information certified by the Board of Directors.



MSK A & Associates LLP

(Formerly known as M S K A & Associates)

Chartered Accountants

HO

602, Floor 6, Raheja Titanium
Western Express Highway, Geetanjali
Railway Colony, Ram Nagar, Goregaon (E)
Mumbai 400063, INDIA
Tel: +91 22 6974 0200

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)

Chartered Accountants

ICAI Firm Registration No.105047W/W101187



Gjas D. Joshi

Partner

Membership No.: 109752

UDIN: 26109752P2MCPB2433

Place: Navi Mumbai

Date: May 07, 2026



Statement of Audited Consolidated Financial Results for the Quarter and Year Ended 31 March 2026


(Rs. in Crores)

Particulars	Quarter ended			Year ended	Year ended
	31 March 2026 (Audited)	31 December 2025 (Reviewed)	31 March 2025(Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)
Revenue from operations	223.95	195.53	187.16	829.04	687.35
Other Income	4.31	4.98	4.59	16.99	14.83
1 Total income	228.26	200.51	191.75	846.03	702.18
Expenses					
(a) Cost of materials consumed	56.42	47.07	48.71	218.71	188.27
(b) Purchase of stock-in-trade	0.77	0.04	0.46	1.09	2.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(0.51)	0.09	0.30	(0.23)	0.81
(d) Employee benefits expense	36.07	35.76	33.47	138.06	126.77
(e) Finance cost	1.52	(0.09)	0.70	2.80	3.05
(f) Depreciation and amortisation expense	14.03	21.63	13.77	58.58	55.26
(g) Other expenses	56.11	54.74	46.52	209.37	179.14
2 Total Expenses	164.41	159.24	143.93	628.38	555.30
3 Profit before exceptional items, share of profit/ (loss) of associate and jointly controlled entity and income tax	63.85	41.27	47.82	217.65	146.88
Exceptional Items	-	6.16	-	6.16	-
4 Profit before share of profit/ (loss) of associate and jointly controlled entity and income tax	63.85	35.11	47.82	211.49	146.88
Share of profit/ (loss) of associate and jointly controlled	0.58	0.28	(0.63)	1.39	(1.44)
5 Profit before tax	64.43	35.39	47.19	212.88	145.44
6 Tax expense					
(a) Current tax expense (including adjustment of earlier years)	(16.05)	(9.95)	(14.34)	(57.29)	(47.82)
(b) Deferred tax credit/(charge)	0.32	2.61	(11.28)	7.26	(6.87)
7 Profit for the period/year (5 - 6)	48.70	28.05	21.57	162.85	90.75
8 Other Comprehensive income (net of tax)					
(a) Items that will not be reclassified to profit or loss	0.88	(0.19)	(0.31)	0.50	(1.03)
(b) Income tax relating to items that will not be reclassified to profit or loss	(0.22)	0.05	0.08	(0.12)	0.26
9 Total Comprehensive income for the period/ year comprising Profit and other comprehensive income for the period / year (7 + 8)	49.36	27.91	21.34	163.23	89.98
10 Profit/ (Loss) attributable to :					
(a) Owners of the company	47.12	29.01	21.70	163.05	91.51
(b) Noncontrolling interest	1.59	(0.96)	(0.13)	(0.19)	(0.76)
	48.71	28.05	21.57	162.86	90.75
11 Total comprehensive income attributable to :					
(a) Owners of the company	47.77	28.87	21.47	163.42	90.74
(b) Noncontrolling interest	1.59	(0.96)	(0.13)	(0.19)	(0.76)
	49.36	27.91	21.34	163.23	89.98
Paid-up equity share capital (Face Value of Rs. 10/- each)	159.16	159.16	52.99	159.17	52.99
Other equity	-	-	-	426.33	493.76
12 Earnings Per Share (of Rs. 10/- each):#					
(a) Basic (in Rs.)	2.99	1.82	1.39	10.27	5.70
(b) Diluted (in Rs.)	2.98	1.81	1.38	10.24	5.69

#Not audited except for the year ended 31 March 2026 and 31 March 2025.

By order of the Board
For Thyrocare Technologies Limited
CIN - L85110MH2000PLC123882




Rahul Guha
Managing Director
DIN - 09588432
Navi Mumbai, 7 May 2026

Audited Consolidated Statement of Assets and Liabilities as at 31 March 2026

(Rs. in Crores)

Particulars		As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
A	ASSETS		
i	Non-current assets		
(a)	Property, plant and equipment	145.08	148.71
(b)	Capital-work-in progress	3.06	14.15
(c)	Goodwill	108.21	108.21
(d)	Other intangible assets	3.49	4.84
(e)	Right-of-use assets	60.54	35.45
(f)	Investment in associate and jointly controlled entity	25.14	24.17
(g)	Financial assets		
	Other financial assets	6.66	7.89
(h)	Deferred tax assets (net)	15.66	8.53
(i)	Other tax assets	4.31	1.65
(j)	Other non-current assets	2.78	1.43
		374.93	355.03
ii	Current assets		
(a)	Inventories	48.46	46.54
(b)	Financial assets		
	Investments	151.50	137.36
	Trade receivables	73.88	73.00
	Cash and cash equivalents	38.32	17.68
	Bank balances other than cash and cash equivalents	29.84	36.80
	Other financial assets	2.25	1.15
(c)	Other current assets	28.04	25.19
		372.29	337.72
	TOTAL ASSETS	747.22	692.75
B	EQUITY		
i	Equity share capital	159.17	52.99
ii	Other equity	426.33	493.76
iii	Non-controlling interests	0.52	0.30
	Total Equity	586.02	547.05
C	LIABILITIES		
i	Non-current liabilities		
(a)	Financial liabilities		
	Lease liabilities	39.18	16.92
(b)	Provisions	12.11	6.94
		51.29	23.86
ii	Current liabilities		
(a)	Financial liabilities		
	Lease liabilities	11.51	7.76
	Trade payables		
	<i>Total outstanding dues to micro and small enterprises</i>	5.98	2.81
	<i>Total outstanding dues to creditors other than micro and small enterprises</i>	59.39	73.40
	Other financial liabilities	14.45	16.60
(b)	Contract Liabilities	10.69	13.63
(c)	Current tax liabilities (net)	2.38	2.38
(d)	Provisions	1.46	1.00
(e)	Other current liabilities	4.05	4.26
		109.91	121.84
	TOTAL EQUITY AND LIABILITIES	747.22	692.75

By order of the Board
For Thyrocare Technologies Limited
CIN - L85110MH2000PLC123882



Rahul Guha

Rahul Guha
Managing Director
DIN - 09588432
Navi Mumbai, 7 May 2026

Particulars		As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
A.	Cash flows from operating activities		
	Net profit before exceptional items and income tax	212.88	146.88
	Adjustments for:		
	Depreciation and amortisation	58.58	55.26
	Net (gain) on investments	(2.57)	(1.09)
	(Profit)/ Loss on sale of property, plant and equipment	(4.08)	(0.01)
	(Profit) on sale of short term investment	(5.14)	(7.72)
	Impairment loss allowance on financial assets	(1.87)	1.26
	Gain on termination of lease	(0.07)	-
	Finance cost	2.77	3.06
	Interest Income on investments	-	(0.60)
	Employee stock compensation expense	24.09	24.51
	Interest income	(3.07)	(1.39)
	Total of Profit & Loss adjustment	68.64	73.28
	Operating profit before working capital changes	281.52	220.16
	Adjustments for:		
	Decrease/(Increase) in Inventories	(1.92)	0.99
	(Increase)/Decrease in Trade receivables	(0.99)	(30.79)
	(Increase)/Decrease in Other assets	2.74	(26.75)
	Increase in Trade payables	(10.86)	36.10
	Increase in Other liabilities	(3.05)	30.28
	Increase/(Decrease) in Provisions	5.62	1.30
	Net Working Capital Movement	(8.46)	11.13
	Cash generated from operations	273.06	231.29
	Tax paid (net of refunds)	(59.82)	(51.38)
	Net cash flows generated from operating activities (A)	213.24	179.91
B.	Cash flows from investing activities		
	Purchase of property, plant and equipment, additions to capital work in progress and capital advances	(20.88)	(33.48)
	Proceeds from sale of property, plant and equipment	5.40	0.01
	Sale/(Purchase) of current investments (net)	(6.43)	8.20
	Consideration paid on acquisition of Polo and Vinita Business	-	(11.26)
	Investment in associate and jointly controlled entity	-	0.01
	(Investment in)/proceeds from maturity of term deposits	(4.17)	(6.56)
	Interest received	3.07	1.97
	Net cash (used in) investing activities (B)	(23.01)	(41.11)
C.	Cash flows from financing activities		
	Proceeds from issue of equity shares	-	0.04
	Repayment of borrowings	-	(21.59)
	Payment towards principal portion of lease liabilities	(18.39)	(10.49)
	Payment towards interest portion of lease liabilities	(2.77)	(2.64)
	Interest paid	-	(0.43)
	Dividend paid to the shareholders	(148.43)	(95.31)
	Net cash (used in) financing activities (C)	(169.59)	(130.42)
	Net Increase in Cash and cash equivalents (A+B+C)	20.64	8.38
	Cash and cash equivalents at the beginning of the year	17.68	9.30
	Cash and cash equivalents at the end of the year	38.32	17.68



By order of the Board
For Thyrocare Technologies Limited
CIN - L85110MH2000PLC123882

Rahul Guha
Managing Director
DIN - 09588432
Navi Mumbai, 7 May 2026

Notes:

1 Based on the "management approach" as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker evaluates the Group's Performance. The Group has identified business segments as its primary segments. The Group recognizes its diagnostic testing services activity and imaging services including manufacturing of radiopharmaceuticals activity as its primary business segments. Diagnostic testing services operations predominantly consists of providing laboratory testing services to its customers. Imaging services segment represents PET-CT scan and sale of radio pharmaceuticals used in imaging services. Others represents trading and other related business activities. The accounting principles used in the preparation of the financial statements are consistently applied to record revenue and expenditure in individual segments.

(Rs. in Crores)

Particulars	Quarter ended			Year ended	Year ended
	31 March 2026 (Audited)	31 December 2025 (Reviewed)	31 March 2025(Audited)	31 March 2026 (Audited)	31 March 2025 (Audited)
Segment Revenue					
Diagnostic Testing Services	210.22	182.41	172.69	772.53	629.69
Imaging Services	12.48	12.42	13.68	53.14	54.29
Others	1.24	0.70	0.79	3.37	3.37
Total	223.95	195.53	187.16	829.04	687.35
Less : Intersegment Revenue	-	-	-	-	-
Revenue from Operations	223.95	195.53	187.16	829.04	687.35
Segment Results before tax, exceptional items, share of profit/loss of associate and jointly controlled entity and income tax					
Diagnostic Testing Services	58.86	36.82	41.17	197.48	135.51
Imaging Services	(0.30)	(1.10)	2.02	0.67	(4.02)
Others	0.98	0.57	0.03	2.51	0.57
Total	59.54	36.29	43.22	200.66	132.06
Add : Unallocable income net off other unallocable expenditure	4.31	4.98	4.60	16.99	14.82
Total Profit before exceptional items, share of profit/loss of associate and jointly controlled entity and income tax	63.85	41.27	47.82	217.65	146.88
Exceptional items	-	(6.16)	-	(6.16)	-
Share of profit/ (loss) of associate and jointly controlled entity	0.58	0.28	(0.63)	1.39	(1.44)
Profit before tax	64.43	35.39	47.19	212.88	145.44
Segment assets					
Diagnostic Testing Services	514.08	476.57	480.54	514.08	480.54
Imaging Services	192.34	187.46	179.52	192.34	179.52
Others	-	-	-	-	-
Unallocated	40.80	40.11	32.69	40.80	32.69
	747.22	704.14	692.75	747.22	692.75
Segment Liabilities					
Diagnostic Testing Services	147.35	142.52	108.73	147.35	108.73
Imaging Services	11.47	14.86	10.73	11.47	10.73
Others	-	-	-	-	-
Unallocated	2.38	15.14	2.38	2.38	2.38
	161.20	172.52	121.84	161.20	121.84

- The above audited consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 7 May 2026 and subsequently approved by the Board of Directors at its meeting held on 7 May 2026. The statutory auditors of the Group have expressed an unmodified opinion on the audited consolidated financial results for the quarter and year ended 31 March 2026.
- The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between audited figures in respect of the full financial year and the limited reviewed year to date figures up to the quarter ended 31 December 2025 and 31 December 2024 respectively.
- These audited consolidated financial results have been prepared in compliance with Ind AS as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India, to the extent applicable.
- Effective 21 November 2025, The Government of India has consolidated multiple existing labour laws into an unified framework comprising four Labour Codes viz the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 collectively referred to as the 'New Labour Codes'. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations.

The Group has assessed the incremental impact of these changes on the basis of the information available and actuarial valuation report obtained from an independent valuer, consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality, its origination due to regulatory changes and non-recurring nature of this impact, the Group has presented such incremental impact as "Exceptional Items" in the audited consolidated financial results for the year ended 31 March 2026. Accordingly the Exceptional Items includes of Rs. 4.20 Crores as incremental impact of Gratuity arising primarily due to the change in the definition of wages.

Further Exceptional Items also include Rs. 1.96 Crores which are non recurring costs associated with restructuring of capital during the year ended 31 March 2026.



6 During the quarter and year ended 31 March 2026, the Holding Company has forfeited 5,196 equity stock options and 25,172 equity stock options respectively granted to employees under Employee Stock Option schemes but not vested on account of discontinuance of services of these employees, which has been added back to the pool and the same would be available for subsequent distribution subject to statutory rules and regulations, as applicable.

During the year ended 31 March 2026, the Holding Company has allotted 63,074 equity shares of Rs.10/- each pursuant to the exercise of

7 The earning per share in respect of previous quarters / years has been restated considering the allotment of bonus shares and adjustment in respect of outstanding stock options, in line with the requirements of Ind AS 33 "Earnings Per Share".


8 The audited consolidated financial results are available on the website of the Company (www.thyrocare.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com).

By order of the Board

For Thyrocare Technologies Limited
CIN - L85110MH2000PLC123882

Rahul Guha
Managing Director

DIN - 09588432
Navi Mumbai, 7 May 2026





Tests you can trust

Annexure-2

May 07, 2026

To,

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400051
(SYMBOL: THYROCARE)

BSE Limited
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400001
(SCRIP CODE: 539871)

Subject: Declaration with respect to Unmodified Opinion on Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026.

Dear Sir/Madam,

I, Vikram Gupta, Chief Financial Officer of the Company, hereby declare that M/s. M S K A & Associates, Chartered Accountants, Statutory Auditors of the Company have issued unmodified opinion/unqualified opinion on the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026.

This declaration is given in accordance with Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the same on record.

Thanking you,

Yours Faithfully,
For Thyrocare Technologies Limited,


Vikram Gupta
Chief Financial Officer

Thyrocare Technologies Limited

📍 D-37/1, TTC MIDC, Turbhe, Navi Mumbai- 400 703, India 📞 022- 3090 0000

✉ info@thyrocare.com 🌐 www.thyrocare.com

Annexure-3

Disclosure under Sub-Para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Appointment of M/s. Price Waterhouse Chartered Accountants LLP, as the Statutory Auditors of the Company for first term of five consecutive years

a)	Name of the Auditor	M/s Price Waterhouse Chartered Accountants LLP
b)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	<p>Appointment</p> <p>M/s. M S K A & Associates LLP, Chartered Accountants (ICAI Firm Registration No. 105047W/W101187), the current Statutory Auditors of the Company, shall complete their first term of five consecutive years at the conclusion of the 26th Annual General Meeting (“AGM”) of the Company to be held in the calendar year 2026.</p> <p>Accordingly, based on the recommendation of the Audit Committee, the Board has approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP, Chartered Accountants (ICAI Firm Registration No. 012754N/N500016), - as the Statutory Auditors of the Company for a term of five consecutive years commencing from the conclusion of the 26th AGM, subject to approval of the shareholders at the ensuing AGM.</p>
c)	Date of appointment, re-appointment/cessation (as applicable) & term of appointment, re-appointment;	Based on the recommendation of the Audit Committee, the Board has considered and approved, and further recommended to the shareholders for their approval at the ensuing Annual General Meeting (“AGM”), the appointment of M/s. Price Waterhouse Chartered Accountants LLP (ICAI Firm Registration No. 012754N/N500016) as the Statutory Auditors of the Company for first term of five consecutive years, commencing from the conclusion of the 26 th AGM (to be held in the calendar year 2026) until the conclusion of the 31 st AGM (to be held in the calendar year 2031), subject to the approval of the shareholders and other applicable statutory requirements.
d)	Brief profile (in case of appointment);	<p>M/s. Price Waterhouse Chartered Accountants LLP, (the “Firm”) having a Firm Registration No. 012754N/N500016, is a firm of Chartered Accountants registered with the Institute of Chartered Accountants of India. The Firm was established in the year 1991 and was converted into a limited liability partnership in the year 2014. The registered office of the Firm is at Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi - 110 002 and has seventeen (17) branch offices in various cities in India.</p> <p>The Firm is primarily engaged in providing auditing and other assurance services to its clients and is a member firm of Price Waterhouse & Affiliates, a network of firms registered with the</p>

Tests you can trust

		Institute of Chartered Accountants of India having Network Registration No. NRN/E/14. Price Waterhouse & Affiliates is a network of separate, distinct and independent Indian Chartered Accountant firms, each of which is registered with the Institute of Chartered Accountants of India. The Firm has more than 125 Assurance Partners as of December 31, 2025. It has a valid peer review certificate and audits various companies listed on stock exchanges in India.
e)	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Disclosure under Sub-Para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Appointment of Cost Auditors of the Company

a)	Name of the Auditor	M/s. Jitender Navneet & Co. Cost Accountants
b)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment
c)	Date of appointment, re-appointment/cessation (as applicable) & term of appointment, re-appointment;	Date of Appointment – May 07, 2026 Term of Appointment – For the Financial Year 2026-27
d)	Brief profile (in case of appointment);	<p>M/s. Jitender, Navneet & Co. is a firm of Cost Accountants registered with the Institute of Cost Accountants of India. The firm is engaged in the field of cost audit, management consultancy, and advisory services. It is empanelled with various regulatory and financial institutions and has experience in handling cost audits and related assignments across industries.</p> <p>The firm is also registered with the PCAOB (USA) and is empanelled with authorities such as the Income Tax Department (including for assignments under Section 142(2A) of the Income-tax Act, 1961), IFCI (for PLI schemes), and GST authorities as Special Auditors.</p> <p>The firm was established in 2003 and has carried out assignments on a pan-India basis.</p> <p>Mr. Navneet Kumar Jain, Managing Partner of the firm, is currently serving as a Member of the Central Council of the Institute of Cost Accountants of India (ICMAI).</p>
e)	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Disclosure under Sub-Para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Re-Appointment of Mr. Rahul Franklin Guha (DIN: 09588432), as Chairman, Managing Director & CEO of the Company

a)	Name & Designation	Mr. Rahul Franklin Guha (DIN:09588432), Chairman, Managing Director & CEO
b)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Re-appointment
c)	Date of appointment, re-appointment, cessation (as applicable) & term of appointment, re-appointment;	Effective Date of Re-Appointment – May 04, 2027 Term of re-appointment: Five (5) years (from May 4, 2027 to May 3, 2032), subject to approval of shareholders at the ensuing AGM.
d)	Brief profile (in case of appointment);	<p>Mr. Rahul Franklin Guha is the Chairman, Managing Director & Chief Executive Officer of the Company and has over 27 years of experience across healthcare, life sciences, and technology-driven businesses. He also serves as Managing Director & CEO at API Holdings Limited (the ultimate holding company), and is responsible for driving the diagnostics business across the group, including Thyrocare, and enabling synergies among group companies. He plays a key role in driving growth, operational excellence, and digital transformation initiatives.</p> <p>Prior to joining the Company, he was associated with Boston Consulting Group (BCG), where he served as Senior Partner and led the Healthcare and Life Sciences practice in India. During his tenure, he advised leading organizations on strategy, organizational transformation, and operational efficiency.</p> <p>He has also co-founded Nautilus Software Solutions and served as Chief Technology Officer at Valuepay.com, bringing strong entrepreneurial and technology leadership experience.</p> <p>Mr. Guha holds a Post Graduate Diploma in Management from the Indian Institute of Management, Bengaluru, and a Bachelor's degree in Engineering from the University of Mumbai.</p>
e)	Disclosure of relationships between directors (in case of appointment of a director).	Nil

Disclosure under Sub-Para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Appointment of Mr. Uday Patel Kadam (DIN: 09277168) as an Additional Director (Non-Executive, Non-Independent Director)

a)	Name & Designation	Mr. Uday Patel Kadam Non-Executive, Non-Independent Director
b)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment
c)	Date of appointment/ re-appointment/cessation (as applicable) & term of appointment/ re-appointment;	Date of Appointment – May 08, 2026 Term of Appointment – Not Applicable
d)	Brief profile (in case of appointment);	<p>Mr. Uday Patel Kadam is a seasoned business leader with over 18 years of diverse experience across healthcare, technology, telecom and financial services sectors, with strong expertise in business strategy, P&L management, operations and supply chain. He is currently associated with API Holdings Limited as Chief Operating Officer & Chief Business Officer, where he is responsible for driving business strategy, operational excellence and growth initiatives, with end-to-end accountability for key business verticals, including supply chain and procurement functions.</p> <p>Prior to this, he has held leadership roles at Ninjacart as Business Head – Ninja Kisaan Platform, where he played a key role in building and scaling platform-led businesses and managing large-scale supply chain operations across India. Earlier, he was associated with Bharti Airtel for over six years in various senior leadership roles across sales, marketing, finance and business operations, including Head of Sales & Distribution (Karnataka) and Chief Commercial Officer – Airtel Mumbai. He began his career with HSBC and Deutsche Bank in finance and credit risk functions. Mr. Kadam holds a Master of Business Administration (MBA) from the Indian School of Business and brings strong leadership capabilities and strategic acumen, which will be valuable to the Company.</p>
e)	Disclosure of relationships between directors (in case of appointment of a director).	Nil

Disclosure under Sub-Para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Appointment of Mr. Gaurav Verma (DIN: 11692586), as an Additional Director (Non-Executive, Non-Independent Director)

a)	Name & Designation	Mr. Gaurav Verma Non-Executive, Non-Independent Director
b)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment
c)	Date of appointment, re-appointment/cessation (as applicable) & term of appointment, re-appointment;	Date of Appointment – May 08, 2026 Term of Appointment – Not Applicable
d)	Brief profile (in case of appointment);	<p>Mr. Gaurav Verma is a seasoned business leader with over 19 years of experience in marketing, consumer strategy and business leadership across the healthcare, food-tech and FMCG sectors. He currently serves as Chief Business Officer at API Holdings Limited (PharmEasy), where he is responsible for driving business growth, consumer strategy, and key strategic initiatives across e-pharmacy, e-diagnostics, partnerships and other healthcare initiatives of the platform business. He previously served as Chief Marketing Officer at PharmEasy, playing a key role in brand building, customer engagement and growth during a transformative phase of the business.</p> <p>Prior to API Holdings, he held senior leadership roles at Zomato as Chief Marketing Officer, and subsequently as Global Growth Head (Dining Out). Before Zomato, he spent over nine years at PepsiCo, where he led marketing for marquee brands such as Kurkure, Lay's and Tropicana. He began his career with ITC and has also worked with Tata Tea Limited and Lenovo.</p> <p>Mr. Verma holds a Post Graduate Program in Management from the Indian Institute of Management, Bangalore, and a B.Tech in Electronics from the Indian Institute of Technology, Madras. His expertise in consumer insights, brand building and business scaling will add significant value to the Company.</p>
e)	Disclosure of relationships between directors (in case of appointment of a director).	Nil

April 30, 2026

To,
The Board of Directors,
Thyrocare Technologies Limited
D-37 /1, TTC MIDC Industrial Area,
Turbhe, Navi Mumbai - 400703
Maharashtra, India

Subject: Resignation from the Directorship of the Company

Dear Board Members,

At the outset, I wish to express my gratitude to the Company and its shareholders for the opportunity to serve as a Non-Executive Non-Independent Director on the Board of Thyrocare Technologies Limited ("the Company").


Due to preoccupation and other professional commitments, I hereby tender my resignation from the position of Non-Executive Non-Independent Director, with effect from the close of business hours on May 07, 2026. Consequently, I shall also cease to be a member of the following Board Committees with effect from the said date:

- Nomination and Remuneration Committee
- Stakeholders Relationship Committee
- Risk Management Committee

I confirm that there is no other material reason for my resignation other than what has been stated above.

I sincerely thank the Board of Directors and the management team of the Company for their continuous support and cooperation during my tenure. I wish the Company continued growth and success in the future.

Thanking you,
Yours faithfully,



Dharmil Nirupam Sheth
DIN: 06999772

Disclosure under Sub-Para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Resignation of Mr. Dharmil Nirupam Sheth (DIN: 06999772), Non-Executive, Non-Independent Director of the Company

a)	Name & Designation	Mr. Dharmil Nirupam Sheth, (DIN: 06999772) Non-Executive, Non-Independent Director
b)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Resignation
c)	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	Effect from close of business hours on May 07, 2026
d)	Brief profile (in case of appointment);	Not Applicable
e)	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

April 30, 2026

To,
The Board of Directors,
Thyrocare Technologies Limited
D-37 /1, TTC MIDC Industrial Area,
Turbhe, Navi Mumbai - 400703
Maharashtra, India

Subject: Resignation from the Directorship of the Company

Dear Board Members,

At the outset, I wish to express my gratitude to the Company and its shareholders for the opportunity to serve as a Non-Executive Non-Independent Director on the Board of Thyrocare Technologies Limited ("the Company").


Due to preoccupation and other professional commitments, I hereby tender my resignation from the position of Non-Executive Non-Independent Director, with effect from the close of business hours on May 07, 2026. Consequently, I shall also cease to be a member of the following Board Committees with effect from the said date:

- Corporate Social Responsibility Committee

I confirm that there is no other material reason for my resignation other than what has been stated above.

I sincerely thank the Board of Directors and the management team of the Company for their continuous support and cooperation during my tenure. I wish the Company continued growth and success in the future.

Thanking you,
Yours faithfully,



Dhaval Shah
DIN: 07485688

Disclosure under Sub-Para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Resignation of Dr. Dhaval Rajesh Shah (DIN: 07485688), Non-Executive, Non-Independent Director of the Company

a)	Name & Designation	Dr. Dhaval Rajesh Shah, (DIN: 07485688) Non-Executive, Non-Independent Director
b)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Resignation
c)	Date of appointment/re-appointment/cessation. (as applicable) & term of appointment/re-appointment;	Effect from close of business hours on May 07, 2026
d)	Brief profile (in case of appointment);	Not Applicable
e)	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Disclosure under Sub-Para (1) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Investment in the equity shares of Think Health Diagnostics Private Limited, a Wholly Owned Subsidiary of the Company

S.No	Particulars	Description
1	Name of the Target Company, details in brief such as size, turnover, etc.	<p>Think Health Diagnostics Private Limited (“Think Health”) is a wholly owned subsidiary of the Company.</p> <p>Think Health is in the process of establishing a dedicated diagnostics platform, with an initial focus on affordable, high-volume testing, including thyroid and routine pathology segments.</p> <p>Turnover for the year ended March 31, 2026: Rs. 0.01 Crores.</p>
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm length”	<p>Yes, the proposed investment by way of subscription to equity shares of Think Health is a related party transaction.</p> <p>Except to the extent of shareholding held by the Company in Think Health, the promoters/promoter group do not have any other interest in the said entity. The transaction will be carried out at arm’s length.</p>
3	Industry to which the entity being acquired belongs	Healthcare Services
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The proposed equity infusion in Think Health is intended to support its business operations and to meet its capital expenditure and working capital requirements.
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
6	Indicative time for completion of the acquisition	In one or more tranches, as and when required
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration
8	Cost of acquisition or the price at which the shares are acquired	Up to Rs. 5.50 crores,
9	Percentage of shareholding/ control acquired and/or number of shares acquired	No change; Think Health will continue to be a wholly owned subsidiary of the Company
10	Brief background about the entity acquired in terms of products/line of	Date of Incorporation: June 07, 2022

Tests you can trust

	<p>business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)</p>	<p>Think Health is focused on building a diagnostics platform with emphasis on affordable, accessible and high-volume testing services.</p> <p>Country of presence: India</p> <p>The turnover of Think Health for last 3 years is given below:</p> <table border="1" data-bbox="798 481 1252 665"> <thead> <tr> <th>Year</th> <th>Turnover (Rs. in Crore)</th> </tr> </thead> <tbody> <tr> <td>2025-26</td> <td>0.01</td> </tr> <tr> <td>2024-25</td> <td>0.83</td> </tr> <tr> <td>2023-24</td> <td>3.35</td> </tr> </tbody> </table>	Year	Turnover (Rs. in Crore)	2025-26	0.01	2024-25	0.83	2023-24	3.35
Year	Turnover (Rs. in Crore)									
2025-26	0.01									
2024-25	0.83									
2023-24	3.35									